Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Leary

Showing results (221-230 of 285) with videos related to

Pageof 29
Sort By:
Pulmonary Pharmacology & Therapeutics|December 1, 2020
An expert panel delphi consensus statement on patient selection and management for transitioning between oral and inhaled treprostinilFranck F Rahaghi, Roblee P Allen, Vijay P Balasubramanian, et al.
BMC Infectious Diseases|December 26, 2001
Absence of rapid selection for acyclovir or penciclovir resistance following suboptimal oral prodrug therapy of HSV-infected miceR T Sarisky, H R Bartus, S A Dennis, et al.
Respiratory Medicine|March 19, 2023
Establishing a balloon pulmonary angioplasty program for chronic thromboembolic pulmonary hypertension: A United States single-center experienceLauren N Carlozzi, Josh Lee, Lia M Barros, et al.
Annals of the American Thoracic Society|September 8, 2023
Regional Variation in Pulmonary Arterial Hypertension in the United States: The Pulmonary Hypertension Association RegistryConnor Fling, Teresa De Marco, Noah A Kime, et al.
Circulation. Heart Failure|October 22, 2024
Proteomic Signatures of Right Ventricular Outcomes in Pulmonary Arterial HypertensionHongyang Pi, Lu Xia, Olivier Boucherat, et al.
Antimicrobial Agents and Chemotherapy|May 11, 1992
Human immunodeficiency virus type 1 protease inhibitors irreversibly block infectivity of purified virions from chronically infected cellsD M Lambert, S R Petteway, C E McDanal, et al.
The American Journal of Cardiology|September 22, 2012
Von Willebrand factor and the right ventricle (the MESA-Right Ventricle Study)Peter J Leary, R Graham Barr, David A Bluemke, et al.
Chest|January 6, 2025
Effect of Famotidine on Outcomes in Pulmonary Arterial Hypertension: A Randomized Controlled TrialPeter J Leary, Samuel G Rayner, Kelley R H Branch, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 17, 2001
Biochemical characterization of a virus isolate, recovered from a patient with herpes keratitis, that was clinically resistant to acyclovirR T Sarisky, R Cano, T T Nguyen, et al.
Annals of the American Thoracic Society|July 30, 2020
A Survey-based Estimate of COVID-19 Incidence and Outcomes among Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension and Impact on the Process of CareJoshua D Lee, Charles D Burger, Genecelle B Delossantos, et al.
Pageof 29

Showing results (221-230 of 285) with videos related to

Sort By:
Pageof 29
Pulmonary Pharmacology & Therapeutics|December 1, 2020
An expert panel delphi consensus statement on patient selection and management for transitioning between oral and inhaled treprostinilFranck F Rahaghi, Roblee P Allen, Vijay P Balasubramanian, et al.
BMC Infectious Diseases|December 26, 2001
Absence of rapid selection for acyclovir or penciclovir resistance following suboptimal oral prodrug therapy of HSV-infected miceR T Sarisky, H R Bartus, S A Dennis, et al.
Respiratory Medicine|March 19, 2023
Establishing a balloon pulmonary angioplasty program for chronic thromboembolic pulmonary hypertension: A United States single-center experienceLauren N Carlozzi, Josh Lee, Lia M Barros, et al.
Annals of the American Thoracic Society|September 8, 2023
Regional Variation in Pulmonary Arterial Hypertension in the United States: The Pulmonary Hypertension Association RegistryConnor Fling, Teresa De Marco, Noah A Kime, et al.
Circulation. Heart Failure|October 22, 2024
Proteomic Signatures of Right Ventricular Outcomes in Pulmonary Arterial HypertensionHongyang Pi, Lu Xia, Olivier Boucherat, et al.
Antimicrobial Agents and Chemotherapy|May 11, 1992
Human immunodeficiency virus type 1 protease inhibitors irreversibly block infectivity of purified virions from chronically infected cellsD M Lambert, S R Petteway, C E McDanal, et al.
The American Journal of Cardiology|September 22, 2012
Von Willebrand factor and the right ventricle (the MESA-Right Ventricle Study)Peter J Leary, R Graham Barr, David A Bluemke, et al.
Chest|January 6, 2025
Effect of Famotidine on Outcomes in Pulmonary Arterial Hypertension: A Randomized Controlled TrialPeter J Leary, Samuel G Rayner, Kelley R H Branch, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 17, 2001
Biochemical characterization of a virus isolate, recovered from a patient with herpes keratitis, that was clinically resistant to acyclovirR T Sarisky, R Cano, T T Nguyen, et al.
Annals of the American Thoracic Society|July 30, 2020
A Survey-based Estimate of COVID-19 Incidence and Outcomes among Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension and Impact on the Process of CareJoshua D Lee, Charles D Burger, Genecelle B Delossantos, et al.
Pageof 29